Author

T. Canassa-DeLeo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

C. A. Fuzo· 1 shared E. A. Neto· 1 shared J. P. Souza· 1 shared L. H. Faccioli· 1 shared M. Dias-Baruffi· 1 shared M. K. Amstalden· 1 shared R. B. Martins· 1 shared S. C. Franca· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

C. A. Fuzo

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Drug repurposing to face Covid-19: Celastrol, a potential leading drug capable of inhibiting SARS-CoV-2 replication and induced inflammation

C. A. Fuzo, R. B. Martins, T. F. C. Fraga-Silva, M. K. Amstalden, T. Canassa-DeLeo, J. P. Souza, T. M. Lima, L. H. Faccioli, S. C. Franca, V. L. D. Bonato, E. A. Neto, M. Dias-Baruffi

This paper identifies celastrol as a potential drug for treating Covid-19 by inhibiting SARS-CoV-2 replication and reducing IL-6 secretion in infected cells.

bioRxiv · Apr 20, 2021Immunology